SIRPA and melanoma: designed a stable supramolecular structure named AK750, which sustainably blocked CSF‐1R to switch CD11b+CD206+M2‐like TAMs into CD11b+MHCII+CD80+CD86+ M1 phenotype in the B16F10 melanoma.[101] Engineering anti‐SIRPα antibody with AK750 (anti‐SIRPα‐AK750) could further enhance TAMs‐targeting, repolarization and tumor‐phagocytosis capability.